INTARCIA THERAPEUTICS, INC. WILL WITHDRAW INITIAL PUBLIC OFFERING

The initial public offering of Intarcia Therapeutics Inc. was pulled due to market conditions, an underwriter said on Wednesday. The biopharmaceutical company had filed for an offering of 5 million shares at an estimated price of $12 to $14 each. The deal was initially expected to price on Tuesday. The Emeryville, California-based company develops new uses or alternative formulations for clinical-stage products licensed from major pharmaceutical companies, focusing on products for the treatment of cancer and infectious diseases. Reuters (http://today.reuters.com/investing/financeArticle.aspx?type=newIssuesNews&storyID=URI:urn:newsml:reuters.com:20050921:MTFH67323_2005-09-21_22-40-47_N21322500:1)